Conjugation of functionalized spions with transferrin for targeting and imaging brain glial tumors in rat model

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Jiang, Weili ^a   Xie, Hui ^b   Ghoorah, Devina ^a   Shang, Yalei ^a   Shi, Haojun ^a   Liu, Fang ^a   Yang, Xiangliang ^a   Xu, Haibo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b China Patent Information Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC FERROCYANIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERRIN; TRANSFERRIN CONJUGATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DEXTRAN; DIAGNOSTIC AGENT; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONJUGATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOPLASM; GLIOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; ANIMAL; BRAIN TUMOR; METHODOLOGY; WISTAR RAT;

RATTUS;

ANIMALS; BRAIN NEOPLASMS; CONTRAST MEDIA; DEXTRANS; FERRIC COMPOUNDS; GLIOMA; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; NEUROIMAGING; RATS; RATS, WISTAR; TRANSFERRIN;

EID: 84861205928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037376     Document Type: Article

References (28)

1. Rees J, (2003) Advances in magnetic resonance imaging of brain tumors. Curr Opin Neurol 16: 643-50.
2. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck LJ, (2006) Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24: 1228-35.
3. Kreuter J, (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47: 65-81.
4. High WA, Ayers RA, Chandler J, Zito G, Cowper SE, (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26.
5. Moore A, Marecos E, Bogdanov A Jr, Weissleder R, (2000) Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214: 568-74.
6. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, et al. (2002) Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 23: 510-9.
7. Corot C, Robert P, Idée JM, Port M, (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 58: 1471-1504.
8. Muldoon LL, Sàndor M, Pinkston KE, Neuwelt EA, (2005) Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery 57: 785-96.
9. Huh YM, Jun YW, Song HT, Kim S, Choi JS, et al. (2005) In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 127: 12387-91.
10. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, et al. (2006) Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer. Adv Mater 18: 2553-6.
11. Koo YE, Reddy GR, Bhojani M, Schneider R, Philbert MA, et al. (2006) Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 58: 1556-77.
12. Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, et al. (2011) Lactoferrin- conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32: 495-502.
13. Qian ZM, Li H, Sun H, Ho K, (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54: 561-87.
14. Inoue T, Cavanaugh PG, Steck PA, Brünner N, Nicolson GL, (1993) Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156: 212-7.
15. Recht L, Torres CO, Smith TW, Raso V, Griffin TW, (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72 (6): 941-5.
16. Chirasani SR, Markovic DS, Synowitz M, Eichler SA, Wisniewski P, et al. (2009) Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells. J Mol Med(Berl) 87: 153-67.
17. Yoon DJ, Kwan BH, Chao FC, Nicolaides TP, Philips JJ, et al. (2010) Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res 70: 4520-7.
18. Xia Q, Yang XW, Yang XD, Qian ZM, Wang K, (2009) Drug delivery via the transferrin receptor-mediated endocytosis pathway. Journal of Chinese Pharmaceutical Sciences 18: 7-13.
19. Descamps L, Dehouck MP, Torpier G, Cecchelli R, (1996) Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol 270: H1149-58.
20. Ulbrich K, Hekmatara T, Herbert E, Kreuter J, (2009) Transferrin- and transferrin- receptor- antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71: 251-6.
21. Burtea C, Laurent S, Vander Elst L, Muller RN, (2008) Contrast agents: magnetic resonance. Handb Exp Pharmacol 185: 135-65.
22. Jung CW, Jacobs P, (1995) Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 13 (5): 661-74.
23. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, et al. (2008) In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4: 372-9.
24. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, (1999) A physiological barrier distal to the anatomic blood- brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol 20: 217-22.
25. Gao HL, Pang ZQ, Fan L, Hu KL, Wu BX, et al. (2010) Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin 31: 237-43.
26. Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee JM, et al. (2006) Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 41: 313-24.
27. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, et al. (2008) Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29: 487-96.
28. Benda P, Lightbody J, Sato G, Levine L, Sweet W, (1968) Differentiated Rat Glial Cell Strain in Tissue Culture. Science 161: 370-371.